HeyJaredMichael Smith
- Indexed articles, last 90 days
- 27
- Latest publication
- Sep 18, 2026
- Outlet visibility, for Australian Financial Review
- Top 50K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
They save lives, but nobody knows them. Tom Dery wants to change that (opens the original)
Read excerpt
Tom Dery, marketing guru turned philanthropist, spent decades promoting some of Australia’s biggest corporate names. Now the man who launched one of the nation’s advertising powerhouses, M&C Saatchi in Australia, and went on to work for Qantas and Ansett, is using his talents to market a group of men and women who fly under the public radar despite their enormous achievements. Gift 5 articles to anyone you choose each month when you subscribe.
Calvary Health Care consortium wins the battle for Healthscope (opens the original)
Read excerpt
A consortium of hospital operators and property investors led by Calvary Health Care will take ownership of Healthscope in November after lenders to Australia’s second-largest private hospital operator backed their revised offer for the company, ending 16 months of uncertainty about its future. Lenders who are owed more than $1.6 billion voted in favour of the bid that was agreed after months of negotiating over the price. It kills off a management-led proposal, previously approved by receivers
Big pharma eyes Australian biotech as $300b patent cliff looms (opens the original)
Read excerpt
When Swiss pharmaceutical giant Novartis paid more than $2 billion for cancer therapy company Myricx last month, it was a wake-up call for Australian venture capital and superannuation funds which have had mixed luck with the notoriously risky biotech sector. While Myricx is London-based, the company was seeded with Australian capital. Early-stage investors Brandon Capital and superannuation funds including Hostplus, HESTA and Aware Super received more than $300 million from the deal, a substant
Dennis Bastas reaps $300m dividend from health empire despite losses (opens the original)
Read excerpt
Dennis Bastas’ DBG Health paid $300 million in dividends to the billionaire last financial year, despite the group posting an annual net loss following a change in the valuation of its popular MCoBeauty cosmetics business. The dividend payment was linked to the sale of one quarter of DBG Health, which owns the country’s largest generic drug distributor and a stable of beauty brands, to a private capital fund run by BDT & MSD Partners in August last year. Gift 5 articles to anyone you choose each
Novartis lawsuit accuses Australian boss of double-dealing with Bastas (opens the original)
Read excerpt
Novartis sued its former top Australian executive for holding secret talks to take a senior position at Dennis Bastas’ health and beauty empire, DBG Health, at the same time that he was negotiating deals with the company. Matt Zeller ran the Australian operations for the Zurich-listed pharmaceutical giant before becoming chief executive of Arrotex Pharmaceuticals in January. Gift 5 articles to anyone you choose each month when you subscribe.
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Australian Financial Review, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.